Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KLK7 | P49862 | 2/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17309872 | 0.89 | MAPT (0.68) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL1303931 | 0.89 | MAPT (0.68) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL4539252 | 0.88 | FOLH1 (0.69) | FOLH1 | |
| SCHEMBL29072109 | 0.87 | KLK7 (0.60) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL29072115 | 0.87 | KLK7 (0.60) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL12508122 | 0.86 | MAPT (0.61) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL14719982 | 0.86 | MAPT (0.61) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL14719934 | 0.86 | MAPT (0.61) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL14719981 | 0.86 | MAPT (0.61) | MAPTKLK7KLK5ABCB1FOLH1 | |
| SCHEMBL8955505 | 0.86 | KLK7 (0.64) | MAPTKLK7KLK5ABCB1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | disclosed |
| US-20110105516-A1 | POLYMERIZED MICELLES | LES LABORATOIRES SERVIER (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110105516-A1 | POLYMERIZED MICELLES | LES LABORATOIRES SERVIER (FR) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105516-A1 | POLYMERIZED MICELLES | PHOSPHO1, PEBP1, ABCB4 | MAPT 60/4885KLK7 3938/4885KLK5 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.